Karriereverlauf von Stephen Dowd
Ehemalige bekannte Positionen von Stephen Dowd
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
RALLYBIO CORPORATION | Corporate Officer/Principal | 01.11.2021 | 01.09.2023 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | - |
GSK PLC | Corporate Officer/Principal | - | - |
Arecor Ltd.
Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | - |
Ausbildung von Stephen Dowd
University of Cambridge | Masters Business Admin |
University Of Dundee | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GSK PLC | Health Technology |
RALLYBIO CORPORATION | Health Technology |
Private Unternehmen | 2 |
---|---|
Arecor Ltd.
Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Stephen Dowd
- Erfahrung